Rheumatology Book

http://www.fpnotebook.com/

EtanerceptAka: Enbrel

Advertisement

  1. See Also
    1. Infliximab (Remicade)
    2. Adalimumab (Humira)
  2. Indication
    1. Refractory Rheumatoid Arthritis
      1. Combined with Methotrexate and other DMARDs
      2. Corticosteroid sparing in agents
    2. Juvenile Rheumatoid Arthritis
    3. Psoriatic Arthritis
  3. Mechanism
    1. Soluble TNF receptor blocker
  4. Efficacy
    1. Rapid onset and very effective
    2. Arrests XRay progression
    3. Good synergistic effect with Methotrexate
  5. Adverse Effects
    1. Potential risk of infection
    2. No significant adverse effects
  6. Dosing
    1. Preloaded vial or syringe: 25 mg SQ twice weekly or 50 mg SC weekly
  7. Cost
    1. Per vial: $150
    2. Per month: $1200
    3. Per year: $14,000
  8. Monitoring
    1. Consider following Complete Blood Count
  9. References
    1. Bathon (2000) N Engl J Med 343:1586
    2. Weinblatt (1999) N Engl J Med 340:253

Etanercept (C0717758)

Definition (PDQ)A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257809&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257809&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2381" NCI Thesaurus)
Definition (NCI)A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)
ConceptsAmino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121)
MSHC106167
EnglishEtanercept, ETANERCEPT PREPARATION, ETN, Tumor Necrosis Factor Receptor IgG Chimera
Spanishetanercept
Parent ConceptsImmunosuppressive Agents (C0021081), TNFR-Fc fusion protein (C0539397), Other antirheumatics (C0973578), Antirheumatic Agents (C0003191), Fusion protein (C0162768), Drug allergen (C1320237), Anti-tumor necrosis factor alpha drug (C1562242), Tumor Necrosis Factor (TNF) Inhibitors (C1579324)
SourcesMSH, MTH, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Enbrel (C0720193)

ConceptsAmino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121)
MSHC106167
EnglishEnbrel, Immunex brand of etanercept, Wyeth brand of etanercept
SourcesMSH, NCI, PDQ, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree